Company targets both clinical and wellness applications with wearable patch that enables ‘multi-analyte molecular monitoring.’
Healthtech startup Adaptyx Biosciences has raised $14 million in seed financing to advance development of its wearable platform for continuous, multi-analyte molecular monitoring. The new round, which brings the company’s total funding to $23 million, will support research and development, clinical trials and team expansion as it moves toward FDA clearance for its first applications.
Based in Menlo Park, California, Adaptyx is developing a small wearable patch designed to continuously monitor a wide spectrum of molecular biomarkers in real time. The platform is built around synthetic, DNA-based molecular switches that detect and track analytes such as small molecules, hormones, proteins, drugs and electrolytes. By continuously collecting and streaming biochemical data, the patch aims to provide a dynamic view of human physiology and to enable earlier, data-driven interventions in both clinical and consumer health settings.
The global success of continuous glucose monitoring (CGM) technologies has sparked a race to develop consumer and clinical products capable of sensing more than just glucose levels. Recent funding rounds for companies like Biolinq, which secured whopping $100 million round earlier this year, sweat monitoring company Epicore Biosystems and hormone testing startup Eli Health, reflect investors’ appetite for technologies designed to monitor key aspects of health at a molecular level.
Adaptyx says its approach is intended to go far beyond glucose monitoring, establishing what it describes as a programmable biosensing framework capable of scaling across hundreds of molecular targets. The synthetic DNA bioreceptors at the core of the platform undergo predictable, reversible conformational changes upon binding to specific analytes, producing continuous, quantitative signals that can be analyzed in real time. This underlying sensing mechanism enables what Adaptyx calls “lab-grade molecular data” to be captured continuously and translated into actionable insights through AI-driven analytics.
The company highlights several application areas spanning both therapeutic and wellness domains, including cardiology, where continuous monitoring of key markers could support earlier detection of heart failure decompensation and safer medication management. In endocrinology, Adaptyx says that hormone and metabolite profiling could enable more precise control of metabolic and reproductive health.
Adaptyx CEO Dr Vijit Sabnis
Additional applications targeted by the company include real-time monitoring of drug levels and critical care biomarkers for more responsive clinical decision-making, as well as consumer-facing wellness tracking to support stress management, metabolism optimization and recovery monitoring.
“Healthcare suffers from a data deficit,” said Adaptyx CEO Dr Vijit Sabnis. “Lab tests are only snapshots of health and don’t capture the body’s changing physiology, leaving blind spots that prevent addressing many of today’s health challenges. Adaptyx gives patients and clinicians a continuous view of what’s happening inside the body, transforming previously unseen molecular signals into empowering insights.”
Sabnis told us the that the company’s long-term vision is to enable continuous molecular insight, effectively turning the body into its own real-time diagnostic system.
“By tracking biochemical changes like hormones, metabolism, and inflammation continuously, we can catch the earliest signs of physiological decline and support healthier aging long before chronic disease progression accelerates,” he said. “Our first application focuses on cardiometabolic and hormonal biomarker monitoring, where multi-analyte continuous data can help individuals and clinicians manage therapy response and pinpoint causes of dysregulation. Over time, we plan to expand into applications across immune health, in-hospital monitoring, and health and wellness. The modular design of our biowearable platform allows us to roll out additional sensors quickly – each one adding a new dimension to how we understand and maintain whole-body health.”
The company claims its approach automates the discovery and optimization of new biosensors, using AI to compress development timelines from years to weeks. Adaptyx says it plans to grow its analyte library to include hundreds of biomarkers that can be used to develop applications for personalized and preventive medicine, as wellness and healthy aging.
“Each new switch generates structured datasets that make the system smarter and faster, rapidly expanding the analyte library and powering new applications,” said Adaptyx Chief Science Officer Dr Alex Yoshikawa.
Adaptyx’s technology builds on more than a decade of research conducted at Stanford University and the Chan Zuckerberg Biohub by Professors H Tom Soh and Joseph M DeSimone. The company holds an exclusive license to the intellectual property stemming from that work, which provides the scientific basis for its modular biosensor system.
“After 17 years developing this technology in academia, we’re ready to bring continuous molecular monitoring from the lab to real patients,” said Professor Soh. “The ability to continuously track multiple biomarkers simultaneously is a breakthrough that will transform how we understand human health and improve care for everyone.”
The new financing was led by Interlagos, with participation from Overwater Ventures, Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures and Seaside Ventures.
“Engineering a novel device to sense biological datasets fundamentally transforms the way we will measure and deliver healthcare,” said Interlagos CEO Achal Upadhyaya.
“By delivering multi-analyte molecular data in a wearable format, Adaptyx turns monitoring into a living layer of care rather than a periodic event,” said Overwater founder Kristina Simmons. “That step-change sets a new bar for what technology can do for patients and clinicians.”
Photographs courtesy of Adaptyx